PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2017 Apr 1

PMID 28361462

Citations 4

Authors

Xiaomeng Feng

Xia Gao

Yumei Jia

Yuan Xu

Affiliations

Soon will be listed here.

Abstract

Introduction: Peroxisome proliferator-activated receptor-α (PPAR-α) agonists can regulate metabolism and protect the cardiovascular system. This study investigated the effects of PPAR-α agonist fenofibrate on insulin resistance in patients with impaired glucose tolerance (IGT).

Methods: This research evaluated cross-sectional and interventional studies. 191 subjects with IGT were divided into a hypertriglyceridemia group (HTG group, n = 118) and a normal triglyceride (TG) group (NTG group, n = 73). 79 subjects with normal glucose tolerance were recruited as a control group. The HTG group was treated with fenofibrate (200 mg/day) for 12 weeks. The homeostatic model assessment index 2 (HOMA2) and the McAuley index (McA) were calculated.

Results: HOMA2 for β-cell function (HOMA2-%B) was 93.47 ± 26.28, 68.47 ± 21.29, and 79.92 ± 23.15 in HTG, NTG, and control groups, respectively. HOMA2 for insulin sensitivity (HOMA2-%S) was 48.40 (39.70, 68.70), 110.20 (62.55, 141.95), and 101.20 (79.90, 140.10) in HTG, NTG, and control groups, respectively. HOMA2 for insulin resistance (HOMA2-IR) was 2.09 (1.46, 2.52), 0.92 (0.70, 1.61), and 0.99 (0.71, 1.25) in HTG, NTG, and control groups, respectively. McA was 5.05 ± 0.76, 7.99 ± 1.79, and 8.34 ± 1.55 in HTG, NTG, and control groups, respectively. The HTG group had higher HOMA2-%B and HOMA2-IR, and lower HOMA2-%S and McA than NTG and control groups (P < 0.001 for all). Fenofibrate decreased HOMA2-%B and HOMA2-IR and increased HOMA2-%S and McA in the HTG group (HOMA2-%B: from 93.47 ± 26.28 to 89.34 ± 23.53, P = 0.018; HOMA2-%S: from 48.40 (39.70, 68.70) to 56.75 (44.88, 72.53), P < 0.001; HOMA2-IR: from 2.07 (1.46, 2.52) to 1.76 (1.38, 2.30), P < 0.001; McA: from 5.05 ± 0.76 to 9.34 ± 0.88, P < 0.001).

Conclusion: PPAR-α agonists improve parameters of glucoregulation in IGT patients with hypertriglyceridemia.

Citing Articles

Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.

Alarfaj S, Bahaa M, Elmasry T, Elberri E, El-Khateeb E, Hamouda A Drug Des Devel Ther. 2024; 18:5239-5253.

PMID: 39575188 PMC: 11578921. DOI: 10.2147/DDDT.S490772.

Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review.

Deerochanawong C, Kim S, Chang Y Diabetes Metab J. 2024; 48(2):184-195.

PMID: 38273789 PMC: 10995494. DOI: 10.4093/dmj.2023.0168.

Orphan receptor GPR50 attenuates inflammation and insulin signaling in 3T3-L1 preadipocytes.

Yao Z, Meng J, Long J, Li L, Qiu W, Li C FEBS Open Bio. 2022; 13(1):89-101.

PMID: 36333974 PMC: 9811602. DOI: 10.1002/2211-5463.13516.

Hepatic Ago2 Regulates PPARα for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery.

Bhattacharjee J, Borra V, Salem E, Zhang C, Murakami K, Gill R Endocrinology. 2021; 162(4).

PMID: 33567453 PMC: 7875175. DOI: 10.1210/endocr/bqab007.

References

Hotamisligil G . Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2004; 27 Suppl 3:S53-5. DOI: 10.1038/sj.ijo.0802502. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013; 37 Suppl 1:S81-90. DOI: 10.2337/dc14-S081. View

van Raalte D, Li M, Pritchard P, Wasan K . Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res. 2004; 21(9):1531-8. DOI: 10.1023/b:pham.0000041444.06122.8d. View

Abbasi F, Chen Y, Farin H, Lamendola C, Reaven G . Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. Am J Cardiol. 2008; 102(1):64-9. PMC: 2603622. DOI: 10.1016/j.amjcard.2008.02.097. View

Ide T, Tsunoda M, Mochizuki T, Murakami K . Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice. Med Sci Monit. 2004; 10(10):BR388-95. View

Drew B, Rye K, Duffy S, Barter P, Kingwell B . The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012; 8(4):237-45. DOI: 10.1038/nrendo.2011.235. View

Feng X, Gao X, Jia Y, Zhang H, Pan Q, Yao Z . PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Res. 2015; 2015:924131. PMC: 4674611. DOI: 10.1155/2015/924131. View

Meier J . Beta cell mass in diabetes: a realistic therapeutic target?. Diabetologia. 2008; 51(5):703-13. DOI: 10.1007/s00125-008-0936-9. View

Berglund L, Brunzell J, Goldberg A, Goldberg I, Sacks F, Murad M . Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97(9):2969-89. PMC: 3431581. DOI: 10.1210/jc.2011-3213. View

10.

Wallace T, Levy J, Matthews D . Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6):1487-95. DOI: 10.2337/diacare.27.6.1487. View

11.

Gerstein H, Santaguida P, Raina P, Morrison K, Balion C, Hunt D . Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007; 78(3):305-12. DOI: 10.1016/j.diabres.2007.05.004. View

12.

Chan S, Zeng X, Sun R, Jo E, Zhou X, Wang H . Fenofibrate insulates diacylglycerol in lipid droplet/ER and preserves insulin signaling transduction in the liver of high fat fed mice. Biochim Biophys Acta. 2015; 1852(7):1511-9. DOI: 10.1016/j.bbadis.2015.04.005. View

13.

Wan Q, Wang F, Guan Q, Liu Y, Wang C, Feng L . Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial. Diabet Med. 2010; 27(11):1312-7. DOI: 10.1111/j.1464-5491.2010.03107.x. View

14.

Montecucco F, Steffens S, Mach F . Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm. 2008; 2008:767623. PMC: 2442435. DOI: 10.1155/2008/767623. View

15.

Goto M, Morita A, Goto A, Deura K, Sasaki S, Aiba N . Reduction in adiposity, β-cell function, insulin sensitivity, and cardiovascular risk factors: a prospective study among Japanese with obesity. PLoS One. 2013; 8(3):e57964. PMC: 3590246. DOI: 10.1371/journal.pone.0057964. View

16.

Bajaj M, Suraamornkul S, Hardies L, Glass L, Musi N, DeFronzo R . Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 2007; 50(8):1723-31. DOI: 10.1007/s00125-007-0698-9. View

17.

von Eckardstein A, Widmann C . High-density lipoprotein, beta cells, and diabetes . Cardiovasc Res. 2014; 103(3):384-94. DOI: 10.1093/cvr/cvu143. View

18.

Tonkin A, Hunt D, Voysey M, Kesaniemi A, Hamer A, Waites J . Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Am Heart J. 2012; 163(3):508-14. DOI: 10.1016/j.ahj.2011.12.004. View

19.

Monsalve F, Pyarasani R, Delgado-Lopez F, Moore-Carrasco R . Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013; 2013:549627. PMC: 3678499. DOI: 10.1155/2013/549627. View

20.

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A . Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999; 22(6):920-4. DOI: 10.2337/diacare.22.6.920. View